Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment

Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of norma...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of personalized medicine Vol. 11; no. 6; p. 571
Main Authors:	Subhan, Md Abdus, Yalamarty, Satya Siva Kishan, Filipczak, Nina, Parveen, Farzana, Torchilin, Vladimir P.
Format:	Journal Article
Language:	English
Published:	Basel MDPI AG 18-06-2021 MDPI
Subjects:	Antitumor agents Blood vessels Cancer Cancer therapies Drug delivery systems Drugs Hematology Hypoxia Metastasis Nanoparticles Patients Permeability Pharmaceuticals Precision medicine Review Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2075-4426 2075-4426
DOI:	10.3390/jpm11060571